Bio-Techne
Prix: 54.00Entreprise et modèle économique
Bio-Techne Corporation operates in the healthcare sector, specializing in the development and manufacturing of biotechnology products and tools. Its core offerings include proteins, antibodies, and reagents used in research and clinical applications. Major business segments consist of Protein Sciences, Diagnostics, and Clinical Diagnostics, with primary revenue sources stemming from sales of research reagents and instruments. The company serves academic, pharmaceutical, and biotechnology markets.
Profil d’investissement
The investment profile of Bio-Techne is more aligned with balanced investors, given its moderate growth potential and dividend yield. The stock exhibits characteristics suitable for those seeking a mix of capital appreciation and income, though it carries a higher risk profile. Investors may consider a medium to long-term horizon for potential returns, while liquidity remains moderate.
Métriques fondamentales (expérimental)
- BPA (TTM) — bénéfice par action des 12 derniers mois, $
- 0.71 OK
- Chiffre d’affaires QoQ — croissance trimestrielle du chiffre d’affaires
- 5.3% ↑
- Surprise BPA
- -3.6% conforme
- Volatilité 20 j
- 2.8% stable
- Rendement du dividende
- 0.6% faible dernière date ex-dividende: 2026-05-18
Suivre dans le portefeuille
Graphique des prix
| Date | Avant | Après | Raison |
|---|---|---|---|
| 2026-06-05 02:49 | Vendre | Conserver | Mixed performance; cautious outlook due to volatility. |
| 2026-05-30 02:52 | Conserver | Vendre | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-08 15:11 | — | Conserver | Weak fundamentals and negative momentum raise significant concerns. |
| Date | Analyste | Action | Objectif | Prix alors |
|---|---|---|---|---|
| 2026-06-11 09:52 | Piper Sandler | Mettre à jour | — → 65 | 52.5 |
| 2026-05-14 20:21 | RBC Capital | Mettre à jour | — → 62 | 44.74 |
| 2026-05-07 12:07 | Evercore ISI | Objectif abaissé | 54 → 50 | 49.265 |
Rien pour le moment